Paris pre-opening: The rebound is coming!


If Wednesday’s slide (-2.21%) continued yesterday (-0.57%), CAC 40 should try to rebound this morning and exceed 6,500 points as the session ended with a half-mast.

Despite the encouraging recovery of the US index at the end of Thursday’s session, investors are still concerned about the impact of the Fed’s tightening of monetary policy. This week’s highlights. However, two Fed officials, Charles Evans and Raphael Bostic, gave a more modest speech on Thursday, the former mentioning the need for a “measured” approach.

The market is also paying attention to information about the war in Ukraine, especially economic sanctions aimed at Moscow …

Wall street

After a hesitant session, US equities on Thursday were able to close at a slightly higher price after two half-mast sessions in the face of persistent interest rate tensions. The Federal Reserve confirmed the day before that the central bank of the United States has decided to swiftly tighten monetary policy to combat inflation. Operators were a little relieved by the low oil price below $ 100 a barrel and the strong weekly employment in the United States.

At the closing price, the Dow Jones rose from 0.25% to 34,583 points (-0.42% on Wednesday and -0.8% on Tuesday), while the broad S & P 500 index rose from 0.43% to 4,500 points. Biotechnology stocks rose 0.06% to 13,897 points after falling about 5% in the previous two sessions.

Eco and currency

America :
-Weekly unemployment registration. (2:30 pm)
-Consumer credit. (9 pm.)

-German industrial production. (08:00)

Euro / dollar parity reached $ 1.0869 this morning. Brent’s barrel is trading at $ 101.01. One ounce of gold is trading at $ 1,930.

Value to follow

Gensight: Cash and cash equivalents were € 44.3 million as of December 31, 2021 compared to € 37.9 million as of December 31, 2020. The amount of expected future cash flows related to the repayment of our financial obligations is € 12.4 million for less than one year and more than one year. Operating profit increased by 3.6% to € 7.7 million in 2021, compared to € 7.4 million in 2020. This growth is primarily related to the sales generated by LUMEVOQ (GS010) under the Temporary License (Nominal ATU) granted by the State Institution. For drug safety. This sales increased by 20.1% in 2021 to € 5.3 million, compared with € 4.4 million in the previous year.

Genfit: As of December 31, 2021, our cash and cash equivalents were € 258.8 million, compared to € 171 million as of December 31, 2020. Genfit’s operating profit was € 85.6 million, compared to € 7.8 million in 2020. In 2021, it reached € 80.1 million. In 2021, Genfit recorded a positive consolidated operating profit of € 31.8 million compared to an operating loss of € 82.9 million in 2020.

Biosynex: In the first quarter, the group achieved sales of € 110.1 million, an increase of + 47% compared to the first quarter of the previous fiscal year. Sales of Covid-19 products continued to be strong, with sales of 98.2 ME up + 54%. It accounts for 89% of quarterly sales. The fifth wave of the pandemic, boosted by the rise of the more contagious Omicron mutants, has accelerated the use of rapid diagnostic tests (RDTs) and self-tests to prevent transmission. Biosynex was able to anticipate the needs of customers, laboratories, pharmacies, or healthcare organizations and meet strong market demands as new epidemics emerged.

Akwel was able to meet its business growth target, with announced revenues down -1.6% but up + 2.8% over a range and exchange rates. Faced with low visibility and very volatile production levels of manufacturers, the Group’s adaptability and traditional careful inventory management have been able to meet customer demand. The total operating surplus (EBITDA) decreased by -33.2% to 117.1ME. Current operating profit is down -33.8% to € 75.2 million, as expected when annual sales were announced, representing 8.2% of current operating profit, comparable to pre-crisis results. .. This level of profitability continues to position Akwel as one of Europe’s most successful automotive suppliers. Operating income was 70.4 ME and net income attributable to the Group was 51.2 ME (85.5 ME in 2020) after the tax amount fell to 16.3 ME due to the recognition of an impairment loss of 3.7 ME in Sweden’s activities. I did. Net profit of 5.5% of sales.

Stellantis has sold the remaining 25% stake in GEFCO to CMA CGM Group, a world leader in transportation and logistics. “The sale of this non-strategic asset marks the final step in an exit plan from the transportation and logistics division, which began 10 years ago,” declared Carlos Tavares, CEO of Stellantis.

They published their sales / results …

Les Toques Blanches du Monde, Precia, Ucar, Advenis, Agripower, Enensys Technologies, Cofidur, LDC, Les Agences de Papa, Ecomiam, NamR, AdUX, Oncodesign, Osmozis

The latest “RECOS” from analysts ..

Jeffreys lowered Crédit Agricole’s recommendation from “Purchase” to “Hold”, lowered the target price from € 14.80 to € 11.20, and adjusted SG’s recommendation to “Purchase” to “Hold”. Set the target price at 31-25 euros. .. Jeffreys also lowered the price target for BNP Paribas from 77 euros to 67 euros.

The RBC will raise its Sodexo recommendation to “out performance” for “sectoral performance”, but will reduce the target price from € 84 to € 83.
HSBC recommends “holding” for Eurofin’s “lightening”.

Citigroup will adjust Alstom’s target price from € 47 to € 42. Cowen and Company has raised the target price of Sanofi from 98 euros to 109 euros. JP Morgan remains “neutral” in Adidas.

Market information

Visiomed: Successful capital increase of 3.2ME.

Crédit Agricole holds 9.18% of Banco BPM’s capital.

1000mercis: Acquisition bid project for 30 euros.

in short

Gaussin extends the assembly location to Saint Vallier.

MaaT Pharma: Start of new clinical trial.

Deinove expands Phase II trials of DNV3837 in Canada.